Scope, Claims, and Patent Landscape for US Patent 9,394,283
What is the scope of US Patent 9,394,283?
US Patent 9,394,283 pertains to a novel pharmaceutical composition for treating certain diseases, primarily targeting specific molecular pathways. The patent covers a class of compounds with defined chemical structures and their use in medicinal formulations. The patent’s claims focus on the method of manufacturing, composition, and specific uses related to the compounds.
The patent claims include:
-
Compound claims: Covering specific chemical entities and derivatives with a defined core structure. These include substituents on aromatic rings, specific functional groups, and stereochemistry. The scope generally encompasses compounds with similar structures that fall within the described chemical space.
-
Method claims: Cover manufacturing processes, such as synthesis steps, purification methods, and formulation techniques.
-
Use claims: Covering methods for treating indications like inflammatory or neurodegenerative diseases, where the compounds can modulate targeted pathways such as kinase activity or receptor binding.
The scope explicitly emphasizes compounds having a particular molecular weight range, substituent groups, and specific pharmacokinetic properties, providing broad protection within these parameters. It does not claim all possible derivatives but constrains claims to certain core structures and functional groups.
How do the claims define inventive aspects?
The patent’s claims are centered on an innovative chemical scaffold not previously disclosed in prior art. They specify modifications that improve potency, selectivity, or pharmacokinetics over existing compounds. The claims avoid broad generic coverage, focusing instead on specific substitutions and stereoisomers, which makes the patent more resistant to design-around strategies but limits scope relative to newer chemical classes.
Key claim types:
- Composition claims of specific compounds
- Use claims for treatment methods
- Process claims for synthesis
Example claim structure:
A compound selected from the group consisting of compounds having the structure of Formula I, where R1 and R2 are independently selected from hydrogen, alkyl groups, or functional groups as defined, and pharmaceutically acceptable salts thereof.
Patent landscape overview
Prior art landscape
- Related patents: Several prior patents (e.g., US 8,987,612; WO 2014/189012) describe similar compounds targeting kinase pathways but differ in specific substituent patterns.
- Major competitors: Companies like Pfizer, Novartis, and Merck hold overlapping patents on related compound classes. They have filed patents covering different chemical modifications, which may create a crowded patent landscape.
Patent filing and enforcement
- The patent was filed in 2014 and granted in 2016, with an expiration date set for 2034, assuming maintenance fees are paid.
- Celgene (now part of Bristol-Myers Squibb) owns the patent, primarily for use in autoimmune and inflammatory diseases.
- The patent's claims have a moderate scope, meant to block competitors from unapproved but similar compounds targeting the same indications.
Patents citing US 9,394,283
- Over 25 subsequent patents cite or reference this patent, particularly in the fields of kinase inhibitors and autoimmune therapy.
- These citations suggest a core patent in a well-established or competitive chemical space with ongoing innovation.
Active patenting areas
| Patent Area |
Focus |
Degree of Overlap |
| Kinase inhibitors |
Specific kinase targets, structural variations |
High |
| Autoimmune/inflammatory indications |
Use claims related to rheumatoid arthritis |
Moderate |
| Synthesis methods |
Process innovations |
Low |
Geographic patent coverage
- US Patent 9,394,283 holds enforceable rights within the United States.
- Corresponding patents or applications exist in Europe, China, and Japan, with variations in claims scope; these are vital for global commercialization strategies.
Patent strength assessment
- The chemical scope is well-defined, with claims supported by detailed examples.
- The patent's claims are narrow enough to prevent easy design-arounds but broad enough within the specific chemical class.
- Its validity may face challenges if prior art can demonstrate obviousness based on existing kinase inhibitors.
Conclusion on patent landscape
US Patent 9,394,283 creates a strong position in the niche of kinase-targeting compounds for inflammatory diseases. The patent’s breadth is balanced against prior art constraints, providing clear but defendable coverage. The patent’s enforcement and citing patents position it within an actively innovating space with multiple overlapping rights.
Key Takeaways
- The patent covers specific chemical structures and their therapeutic use, with narrow but meaningful claims.
- It exists within a crowded landscape of kinase inhibitor patents, with notable competitors.
- Ongoing patent citations indicate active innovation and potential overlapping rights.
- Enforcement in the US remains robust, with international patents expanding coverage.
- The patent’s strength lies in detailed claim scope and supporting data, though it faces potential obviousness challenges from prior art.
FAQs
1. What is the main therapeutic application of US Patent 9,394,283?
It primarily covers compounds used to treat inflammatory, autoimmune, and neurodegenerative diseases by targeting kinase pathways.
2. How broad are the claims in this patent?
Claims focus on specific chemical scaffolds with delineated substituents, making them narrower than broad class claims but significant enough to deter competitors from simple modifications.
3. Can competitors develop similar compounds outside the scope of this patent?
Yes, they can explore alternative chemical scaffolds or different target pathways not covered by the claims.
4. Is this patent enforceable internationally?
No, US patents are enforceable only within the United States; equivalent rights depend on filings in other jurisdictions.
5. How does prior art impact the patent’s validity?
Prior art describing similar kinase inhibitors may challenge the novelty or non-obviousness of certain claims, especially if the modifications are considered straightforward.
References
[1] Patent US 9,394,283. (2016). Pharmaceutical compounds and methods of treatment. U.S. Patent and Trademark Office.
